These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17455353)

  • 21. Transformation of an active pharmaceutical ingredient upon high-energy milling: A process-induced disorder in Biclotymol.
    Schammé B; Couvrat N; Malpeli P; Dudognon E; Delbreilh L; Dupray V; Dargent É; Coquerel G
    Int J Pharm; 2016 Feb; 499(1-2):67-73. PubMed ID: 26707413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of amorphous content in the pharmaceutical process environment.
    Savolainen M; Jouppila K; Pajamo O; Christiansen L; Strachan C; Karjalainen M; Rantanen J
    J Pharm Pharmacol; 2007 Feb; 59(2):161-70. PubMed ID: 17270070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amorphous trehalose dihydrate by cryogenic milling.
    Megarry AJ; Booth J; Burley J
    Carbohydr Res; 2011 Jun; 346(8):1061-4. PubMed ID: 21492830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of annealing on the stability of amorphous solids: chemical stability of freeze-dried moxalactam.
    Abdul-Fattah AM; Dellerman KM; Bogner RH; Pikal MJ
    J Pharm Sci; 2007 May; 96(5):1237-50. PubMed ID: 17455341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. beta-carotene encapsulation in a mannitol matrix as affected by divalent cations and phosphate anion.
    Sutter SC; Buera MP; Elizalde BE
    Int J Pharm; 2007 Mar; 332(1-2):45-54. PubMed ID: 17095170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms.
    Vollenbroek J; Hebbink GA; Ziffels S; Steckel H
    Int J Pharm; 2010 Aug; 395(1-2):62-70. PubMed ID: 20493937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amorphization of sugar hydrates upon milling.
    Willart JF; Dujardin N; Dudognon E; Danède F; Descamps M
    Carbohydr Res; 2010 Jul; 345(11):1613-6. PubMed ID: 20494339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do co-spray dried excipients offer better lysozyme stabilisation than single excipients?
    Hulse WL; Forbes RT; Bonner MC; Getrost M
    Eur J Pharm Sci; 2008 Mar; 33(3):294-305. PubMed ID: 18262776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of milling and compression on the solid-state Maillard reaction.
    Qiu Z; Stowell JG; Cao W; Morris KR; Byrn SR; Carvajal MT
    J Pharm Sci; 2005 Nov; 94(11):2568-80. PubMed ID: 16200560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds.
    Patterson JE; James MB; Forster AH; Lancaster RW; Butler JM; Rades T
    J Pharm Sci; 2005 Sep; 94(9):1998-2012. PubMed ID: 16052554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on the amorphisation/milling relationship in pharmaceutical materials.
    Descamps M; Willart JF
    Adv Drug Deliv Rev; 2016 May; 100():51-66. PubMed ID: 26826439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG; Law D; Schmitt EA; Qiu Y
    Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of milling conditions on solid-state amorphization of glipizide, and characterization and stability of solid forms.
    Xu K; Xiong X; Zhai Y; Wang L; Li S; Yan J; Wu D; Ma X; Li H
    J Pharm Biomed Anal; 2016 Sep; 129():367-377. PubMed ID: 27454088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
    Cheow WS; Ng ML; Kho K; Hadinoto K
    Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
    Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
    J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
    Anhorn MG; Mahler HC; Langer K
    Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of budesonide nanocluster dry powder aerosols: formulation and stability.
    El-Gendy N; Huang S; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3445-55. PubMed ID: 22619045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of budesonide nanocluster dry powder aerosols: processing.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3425-33. PubMed ID: 22539360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of preparation pathway on the glass forming ability.
    Blaabjerg LI; Lindenberg E; Rades T; Grohganz H; Löbmann K
    Int J Pharm; 2017 Apr; 521(1-2):232-238. PubMed ID: 28232267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.